Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'TOPOTECAN' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 394 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
      Quantitation of camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    2. Zufia, L; Aldaz, A; Giraldez, J
      Separation methods for camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    3. Jung, LL; Zamboni, WC
      Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

      DRUG RESISTANCE UPDATES
    4. Harries, M; Kaye, SB
      Recent advances in the treatment of epithelial ovarian cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    5. Wadler, S
      New developments in the treatment of ovarian cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    6. Takimoto, CH
      Why drugs fail: Of mice and men revisited

      CLINICAL CANCER RESEARCH
    7. Minami, H; Fujii, H; Igarashi, T; Itoh, K; Tamanoi, K; Oguma, T; Sasaki, Y
      Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

      CLINICAL CANCER RESEARCH
    8. Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P
      Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation

      CLINICAL CANCER RESEARCH
    9. Blaney, S; Berg, SL; Pratt, C; Weitman, S; Sullivan, J; Luchtman-Jones, L; Bernstein, M
      A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study

      CLINICAL CANCER RESEARCH
    10. Bookman, MA
      Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    11. Seiter, K; Liu, DL; Feldman, EJ; Siddiqui, AD; Hoang, A; Baskind, P; Kancherla, R; Ahmed, T
      Intravenous bolus topotecan in patients with myelodysplastic syndrome

      LEUKEMIA & LYMPHOMA
    12. Grossi, F; Scolaro, T; Tixi, L; Loprevite, M; Ardizzoni, A
      The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    13. Calvaruso, G; Carabillo, M; Giuliano, M; Lauricella, M; D'Anneo, A; Vento, R; Tesoriere, G
      Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells:The effect of combined treatment with the topoisomerase I-inhibitor topotecan

      INTERNATIONAL JOURNAL OF ONCOLOGY
    14. Distefano, M; Ferlini, C; De Vincenzo, R; Gaggini, C; Mancuso, S; Scambia, G
      Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells

      ONCOLOGY RESEARCH
    15. van Loevezijn, A; Allen, JD; Schinkel, AH; Koomen, GJ
      Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    16. Boucard, M; Pinguet, F; Poujol, S; Romieu, G; Cupissol, D; Astre, C; Culine, S; Bressolle, F
      Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer

      EUROPEAN JOURNAL OF CANCER
    17. Dunphy, FR; Dunleavy, TL; Harrison, BR; Cantrell, CL; Visconti, JL; Pincus, SM; Richart, JM; Petruska, PJ
      Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors

      ANNALS OF ONCOLOGY
    18. van der Lee, I; Smit, EF; van Putten, JWG; Groen, HJM; Schlosser, NJJ; Postmus, PE; Schramel, FMNH
      Single-agent gemcitabine in patients with resistant small-cell lung cancer

      ANNALS OF ONCOLOGY
    19. Huisman, C; Postmus, PE; Giaccone, G; Smit, EF
      A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients

      ANNALS OF ONCOLOGY
    20. Zamboni, WC; Luftner, DI; Egorin, MJ; Schweigert, M; Sezer, O; Richter, T; Natale, JJ; Possinger, K
      The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid

      ANNALS OF ONCOLOGY
    21. Saita, T; Fujito, H; Mori, M
      Determination of topotecan by ELISA

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    22. Oguma, T; Yamada, M; Konno, T; Inukai, K; Nakaoka, M
      High-performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (Exatecan), in mouse plasma

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    23. Ferlini, C; Distefano, M; Pierelli, L; Bonanno, G; Fattorossi, A; Battaglia, A; Mancuso, S; Scambia, G
      A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development

      PHARMACOLOGY & TOXICOLOGY
    24. Popanda, O; Flohr, C; Dai, JC; Hunzicker, A; Thielmann, HW
      A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex

      MOLECULAR CARCINOGENESIS
    25. Larson, RA
      New agents for induction and postremission therapy of acute myeloid leukemia

      LEUKEMIA
    26. Rinaldi, D; Lormand, N; Brierre, J; Cole, J; Barnes, B; Fontenot, F; Buller, E; Rainey, J
      A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)

      CANCER INVESTIGATION
    27. Royce, ME; Hoff, PM; Dumas, P; Lassere, Y; Lee, JJ; Coyle, J; Ducharme, MP; De Jager, R; Pazdur, R
      Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novelcamptothecin analog

      JOURNAL OF CLINICAL ONCOLOGY
    28. de Jongh, FE; Verweij, J; Loos, WJ; de Wit, R; de Jonge, MJA; Planting, AST; Nooter, K; Stoter, G; Sparreboom, A
      Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

      JOURNAL OF CLINICAL ONCOLOGY
    29. Leoni, F; Ciolli, S; Nozzoli, C; Santini, V; Fanci, R; Ferrini, PR
      Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report

      HAEMATOLOGICA
    30. Oberhoff, C; Kieback, DG; Wurstlein, R; Deertz, H; Sehouli, J; van Soest, C; Hilfrich, J; Mesrogli, M; von Minckwitz, G; Staab, HJ; Schindler, AE
      Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study

      ONKOLOGIE
    31. Lee, ST; Jang, JH; Suh, HC; Hahn, JS; Ko, YW; Min, YH
      Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

      AMERICAN JOURNAL OF HEMATOLOGY
    32. Chastagner, P; Kozin, SV; Taghian, A
      Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    33. Bahadori, HR; Green, MR; Catapano, CV
      Synergistic interaction between topotecan and microtubule-interfering agents

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    34. Thomas, RR; Dahut, W; Harold, N; Grem, JL; Monahan, BP; Liang, M; Band, RA; Cottrell, J; Llorens, V; Smith, JA; Corse, W; Arbuck, SG; Wright, J; Chen, AP; Hamilton, JM; Allegra, CJ; Takimoto, CH
      A phase I and pharmacologic study of 9-aminocamptothecin administered as a120-h infusion weekly to adult cancer patients

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    35. Cavazos, CM; Keir, ST; Yoshinari, T; Bigner, DD; Friedman, HS
      Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    36. Thompson, J; Guichard, SM; Cheshire, PJ; Richmond, LB; Poquette, CA; Ragsdale, ST; Webber, B; Lorsbach, R; Danks, MK; Houghton, PJ
      Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    37. Herrington, JD; Figueroa, JA; Kirstein, MN; Zamboni, WC; Stewart, CF
      Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    38. Lokich, J
      Phase I clinical trial of weekly combined topotecan and irinotecan

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    39. Huntington, MO; Krell, KE; Armour, WE; Liljenquist, JE
      Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome - Case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    40. Murphy, BA; Leong, T; Burkey, B; Langer, C; Forastiere, A
      Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck - An Eastern Cooperative Oncology Group trial (E3393)

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    41. Giblin, J; Fanucchi, MP; McGuire, WP
      Clear cell carcinoma of the ovary - A remarkable case

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    42. Kushner, BH; Cheung, NKV; Kramer, K; Dunkel, IJ; Calleja, E; Boulad, F
      Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in childrenand young adults

      BONE MARROW TRANSPLANTATION
    43. Yeoh, EJA; Cunningham, JM; Yee, GC; Hunt, D; Houston, JA; Richardson, SL; Stewart, CF; Houghton, PJ; Bowman, LC; Gajjar, AJ
      Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells

      BONE MARROW TRANSPLANTATION
    44. Lansiaux, A; Bras-Goncalves, RA; Rosty, C; Laurent-Puig, P; Poupon, MF; Bailly, C
      Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: Relation with their sensitivity to CTP-11

      ANTICANCER RESEARCH
    45. Agelaki, S; Kakolyris, S; Palamidas, P; Kouroussis, C; Mavroudis, D; Kalbakis, K; Georgoulias, V; Raptis, A
      A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer

      LUNG CANCER
    46. Miller, AA; Niell, HB
      Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide

      LUNG CANCER
    47. Loprevite, M; Favoni, RE; de Cupis, A; Pirani, P; Pietra, G; Bruno, S; Grossi, F; Scolaro, T; Ardizzoni, A
      Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines

      LUNG CANCER
    48. Vokes, EE; Gordon, GS; Rudin, CM; Mauer, AM; Watson, S; Krauss, S; Arrieta, R; Golomb, HM; Hoffman, PC
      A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

      INVESTIGATIONAL NEW DRUGS
    49. Bayar, N; Boke, B; Apan, A; Koc, MC
      Efficacy of topotecan treatment on an experimental model of transient evoked otoacoustic emissions

      INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
    50. Yawn, BP; Wollan, P; Klee, M; Barrette, B
      Ovarian carcinoma: Care and survival in a community-based population

      CLINICAL THERAPEUTICS
    51. Warmann, SW; Fuchs, J; Wilkens, L; Gratz, KF; von Schweinitz, D; Mildenberger, H
      Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan

      MEDICAL AND PEDIATRIC ONCOLOGY
    52. Rodriguez, M; Rose, PG
      Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer

      GYNECOLOGIC ONCOLOGY
    53. Homesley, HD; Hall, DJ; Martin, DA; Lewandowski, GS; Vaccarello, L; Nahhas, WA; Suggs, CL; Penley, RG
      Dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

      GYNECOLOGIC ONCOLOGY
    54. Hensley, ML; Hoppe, B; Leon, L; Sabbatini, P; Aghajanian, C; Chi, D; Spriggs, DR
      The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients

      GYNECOLOGIC ONCOLOGY
    55. Campos, SM; Penson, RT; Mays, AR; Berkowitz, RS; Fuller, AF; Goodman, A; Matulonis, UA; Muzikansky, A; Seiden, MV
      The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

      GYNECOLOGIC ONCOLOGY
    56. Muderspach, LI; Blessing, JA; Levenback, C; Moore, JL
      A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study

      GYNECOLOGIC ONCOLOGY
    57. Prince, HM; Rischin, D; Quinn, M; Allen, D; Planner, R; Neesham, D; Gates, P; Davison, J
      Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: Results of a Phase I study

      GYNECOLOGIC ONCOLOGY
    58. Kakolyris, S; Kouroussis, C; Souglakos, J; Mavroudis, D; Agelaki, S; Kalbakis, K; Androulakis, N; Vardakis, N; Vamvakas, L; Georgoulias, V
      A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors

      ONCOLOGY
    59. Schiller, JH
      Current standards of care in small-cell and non-small-cell lung cancer

      ONCOLOGY
    60. Huang, CH; Treat, J
      New advances in lung cancer chemotherapy: Topotecan and the role of topoisomerase I inhibitors

      ONCOLOGY
    61. O'Neill, P; Clark, PI; Smith, D; Marshall, E; Hannigan, K; Ross, G
      A phase I trial of a 5-day schedule of intravenous topotecan and etoposidein previously untreated patients with small-cell lung cancer

      ONCOLOGY
    62. Eckardt, JR
      Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer

      ONCOLOGY
    63. Stupp, R; Bodmer, A; Duvoisin, B; Bauer, J; Perey, L; Bakr, M; Ketterer, N; Leyvraz, S
      Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine

      ONCOLOGY
    64. Eckardt, JR
      Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy

      ONCOLOGY
    65. Pujol, JL; von Pawel, J; Tumolo, S; Martoni, A; Hearn, S; Fields, SZ; Ross, G
      Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer

      ONCOLOGY
    66. Schiller, JH
      Future role of topotecan in the treatment of lung cancer

      ONCOLOGY
    67. Greggi, S; Salerno, MG; D'Agostino, G; Ferrandina, G; Lorusso, D; Manzione, L; Mancuso, S; Scambia, G
      Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

      ONCOLOGY
    68. Strel'tsov, SA; Grokhovskii, SL; Kudelina, IA; Oleinikov, VA; Zhuze, AL
      Interaction of topotecan, DNA tapoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 1. Topotecan dimerization in solution

      MOLECULAR BIOLOGY
    69. Strel'tsov, SA; Mikheikin, AL; Nechipurenko, YD
      Interaction of topotecan, DNA tapoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 2. Formation of topotecan-DNA complex containing several DNA molecules

      MOLECULAR BIOLOGY
    70. Xiao, D; Tan, WF; Li, MH; Ding, J
      Antiangiogenic potential of 10-hydroxycamptothecin

      LIFE SCIENCES
    71. Soffer, SZ; Moore, JT; Kim, E; Huang, JZ; Yokoi, A; Manley, C; O'Toole, K; Stolar, C; Middlesworth, W; Yamashiro, DJ; Kandel, JJ
      Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor

      JOURNAL OF PEDIATRIC SURGERY
    72. Soffer, SZ; Kim, E; Moore, JT; Huang, JZ; Yokoi, A; Manley, C; O'Toole, K; Middlesworth, W; Stolar, C; Yamashiro, D; Kandel, J
      Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor

      JOURNAL OF PEDIATRIC SURGERY
    73. Ng, CE; Mazaheri, K; Payant, C; Raaphorst, GP
      Evaluation of cell survival, DNA double strand breaks, and DNA synthesis during concurrent camptothecin and X-radiation treatments

      INTERNATIONAL JOURNAL OF CANCER
    74. Ulukan, H; Muller, MT; Swaan, PW
      Downregulation of topoisomerase 1 in differentiating human intestinal epithelial cells

      INTERNATIONAL JOURNAL OF CANCER
    75. Schmidt, F; Rieger, J; Wischhusen, J; Naumann, U; Weller, M
      Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage

      EUROPEAN JOURNAL OF PHARMACOLOGY
    76. Larsen, AK; Gilbert, C; Chyzak, G; Plisov, SY; Naguibneva, I; Lavergne, O; Lesueur-Ginot, L; Bigg, DCH
      Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells

      CANCER RESEARCH
    77. De Cesare, M; Pratesi, G; Perego, P; Carenini, N; Tinelli, S; Merlini, L; Penco, S; Pisano, C; Bucci, F; Vesci, L; Pace, S; Capocasa, F; Carminati, P; Zunino, F
      Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin

      CANCER RESEARCH
    78. Honjo, Y; Hrycyna, CA; Yan, QW; Medina-Perez, WY; Robey, RW; van de Laar, A; Litman, T; Dean, M; Bates, SE
      Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells

      CANCER RESEARCH
    79. Sun, WJ; Stevenson, JP; Gallagher, M; Giantonio, B; Algazy, K; Haller, D; Vaughn, D; Raskay, BJ; O'Dwyer, PJ
      A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

      CANCER
    80. Kancherla, RR; Nair, JS; Ahmed, T; Durrani, H; Seiter, K; Mannancheril, A; Tse-Dinh, YC
      Evaluation of topotecan and etoposide for non-Hodgkin lymphoma - Correlation of topoisomerase-DNA complex formation with clinical response

      CANCER
    81. Gelderblom, H; Sparreboom, A; de Jonge, MJA; Loos, WJ; Wilms, E; Mantel, MA; Hennis, B; Camlett, I; Verweij, J; van der Burg, MEL
      Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

      BRITISH JOURNAL OF CANCER
    82. Pavillard, V; Kherfellah, D; Richard, S; Robert, J; Montaudon, D
      Effects of the combination of camptothecin and doxorubicin or etoposide onrat glioma cells and camptothecin-resistant variants

      BRITISH JOURNAL OF CANCER
    83. Frasci, G; Nicolella, G; Comella, P; Carreca, I; DeCataldis, G; Muci, D; Brunetti, C; Natale, M; Piantedosi, F; Russo, A; Palmeri, S; Comella, G; Panza, N
      A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

      BRITISH JOURNAL OF CANCER
    84. Gore, M; Rustin, G; Schuller, J; Lane, SR; Hearns, S; Beckman, RA; Ross, G
      Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

      BRITISH JOURNAL OF CANCER
    85. Brehm, BR; Bock, C; Wesselborg, S; Pfeiffer, S; Schuler, S; Schulz-Osthoff, K
      Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan

      BIOCHEMICAL PHARMACOLOGY
    86. Loos, WJ; Kehrer, D; Brouwer, E; Verweij, J; de Bruijn, P; Hamilton, M; Gill, S; Nooter, K; Stoter, G; Sparreboom, A
      Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    87. Blaney, SM; Poplack, DG
      Neoplastic meningitis: diagnosis and treatment considerations

      MEDICAL ONCOLOGY
    88. Worden, FP; Kalemkerian, GP
      Therapeutic advances in small cell lung cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    89. Dejosez, M; Ramp, U; Mahotka, C; Krieg, A; Walczak, H; Gabbert, HE; Gerharz, CD
      Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

      CELL DEATH AND DIFFERENTIATION
    90. Fulco, RA; Costa, C; Germano, MP; Torre, EA; Viscomi, MG; Salimbeni, V; Maisano, R; Giudice, A; Costa, G
      Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes

      JOURNAL OF CHEMOTHERAPY
    91. Emerson, DL; Bendele, R; Brown, E; Chiang, SM; Desjardins, JP; Dihel, LC; Gill, SC; Hamilton, M; LeRay, JD; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B; Luzzio, MJ; Baccanari, D
      Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan

      CLINICAL CANCER RESEARCH
    92. Prescott, DM; Charles, HC; Poulson, JM; Page, RL; Thrall, DE; Vujaskovic, Z; Dewhirst, MW
      The relationship between intracellular and extracellular pH in spontaneouscanine tumors

      CLINICAL CANCER RESEARCH
    93. Ma, MK; Zamboni, WC; Radomski, KM; Furman, WL; Santana, VM; Houghton, PJ; Hanna, SK; Smith, AK; Stewart, CF
      Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan

      CLINICAL CANCER RESEARCH
    94. Vey, N; Giles, FJ; Kantarjian, H; Smith, TL; Beran, M; Jeha, S
      The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia

      CLINICAL CANCER RESEARCH
    95. Itoh, K; Sasaki, Y; Fujii, H; Minami, H; Ohtsu, T; Wakita, H; Igarashi, T; Watanabe, Y; Onozawa, Y; Kashimura, M; Ohashi, Y
      Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer

      CLINICAL CANCER RESEARCH
    96. Houghton, PJ; Stewart, CF; Cheshire, PJ; Richmond, LB; Kirstein, MN; Poquette, CA; Tan, M; Friedman, HS; Brent, TP
      Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models

      CLINICAL CANCER RESEARCH
    97. Malik, IA
      An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    98. Abu-Rustum, NR; Lee, S; Massad, LS
      Topotecan for recurrent cervical cancer after platinum-based therapy

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    99. Eisenhauer, EA
      New cytotoxics and non-cytotoxics in epithelial ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    100. Cortes, J; Estey, E; Beran, M; O'Brien, S; Giles, F; Koller, C; Keating, M; Kantarjian, H
      Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

      LEUKEMIA & LYMPHOMA


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/02/20 alle ore 18:13:36